Companies › Innostellar Biotherapeutics
2 active drug programs in 6 registered trials: 3 Phase 1, 2 Phase 3, 1 Phase 2; Ophthalmology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LX101 Gene therapy for RPE65 mutations | RPE65 | Phase 3 | Inherited Retinal Dystrophy Associated With RPE65 Mutations; Inherited Retinal Dystrophy | Dec 2027 |
| LX102 AAV-based gene therapy encoding VEGF-trap (soluble VEGF receptor fusion protein) | VEGFA | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD); Neovascular Age-Related Macular Degeneration | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06196827 | LX101 | Phase 1 | Inherited Retinal Dystrophy Associated With RPE65 Mutations | Ophthalmology | Dec 2027 |
| NCT07317934 | LX102 | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD) | Ophthalmology | Mar 2028 |
| NCT06198413 | LX102 | Phase 1 | Neovascular Age-Related Macular Degeneration | Ophthalmology | Jan 2029 |
| NCT06212297 | LX101 | Phase 1 | Inherited Retinal Dystrophy | Ophthalmology | Mar 2029 |
| NCT07054632 | LX101 | Phase 3 | Inherited Retinal Dystrophy Associated With RPE65 Mutations | Ophthalmology | Aug 2029 |
| NCT06196840 | LX102 | Phase 2 | Neovascular Age-Related Macular Degeneration | Ophthalmology | Oct 2029 |
Neurotech Pharmaceuticals MeiraGTx Ocular UK Tecnoquimicas Adverum Biotechnologies Price Vision Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.